Drugs / CDX-014
CDX-014
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02837991 | Jun 2016 → Nov 2018 | clear cell renal carcinoma, ovarian clear cell cancer, papillary renal cell carcinoma | Celldex Therapeutics | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CDX-014 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02837991 ↗ |
| Known as | CDX-014-VCMMAE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297719 ↗ |
| Known as | CR014-VC-MMAE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297719 ↗ |
| Route | Intravenous | “CDX-014 was administered intravenously” PMID 32472319 ↗ May 2020 |